Electroacupuncture for Moderate and Severe Benign Prostatic Hyperplasia
Wang Y, et al. Guang'anmen Hospital, China Academy of Chinese
Medical Sciences, Beijing, China.
PURPOSE: To evaluate the effects of electroacupuncture (EA) on the International Prostate Symptom Score (IPSS), postvoid residual urine (PVR), and maximum urinary flow rate (Qmax), and explore the difference between EA at acupoints and non-acupoints in patients with moderate to severe benign prostate hyperplasia (BPH). SUBJECTS AND METHODS: Men with BPH and IPSS ≥8 were enrolled. Participants were randomly allocated to receive EA at acupoint (treatment group, n = 50) and EA at non-acupoint (control group, n = 50). The primary outcome measure includes the change of IPSS at the 6th week and the secondary outcome measures include changes of PVR and Qmax at the 6th week and change of IPSS at the 18th week. RESULTS: 100/192 patients were included. At the 6th week, treatment group patients had a 4.51 (p<0.001) and 4.12 (p<0.001) points greater
decline in IPSS than the control group in the intention to treat (ITT) and per-protocol (PP) populations.
At the 18th week, a 3.2 points (p = 0.001) greater decline was found in IPSS for the treatment. No
significant differences were found between the two groups in Qmax at the 6th week (p = 0.819). No
significant difference was observed in PVR (P = 0.35). CONCLUSION: Acupoint EA at BL 33 had better effects
on IPSS, but no difference on PVR and Qmax as compared with non-acupoint EA. The results indicate that EA
is effective in improving patient's quality of life and acupoint may have better therapeutic effects than
non-acupoints in acupuncture treatments of BPH.
PLoS One.2013 Apr 12;8(4):e59449. doi: 10.1371/journal.pone.0059449. Print 2013.
Effects of Anti-inflammatory and Rehmanniae radix Pharmacopuncture on
Atopic Dermatitis in NC/Nga Mice
Kim MC, et al. Department of Acupuncture and Moxibustion, College of
Korean Medicine, Woosuk University, Wanju, Republic of Korea.
Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by pruritic and erythematous skin lesions. The purpose of this study was to investigate the suppressive effects of anti-inflammatory and Rehmanniae radix pharmacopuncture on the development of AD-like skin lesions in NC/Nga mice. The AD was induced on the mice's back skin by using biostir AD. The experimental groups were divided into three groups, PPI (anti-inflammatory pharmacopuncture), PPII (Rehmanniae radix pharmacopuncture, hydrodistillation extraction) and PPIII (Rehmanniae radix pharmacopuncture, MeOH extraction). All mice were treated using a 1-mL syringe to inject 0.1 mL of pharmacopuncture at right and left acupoints (BL13) on alternate days. In the control group, normal saline was used instead of pharmacopuncture. The following factors were investigated: (1) optical observations made with a handscope and clinical skin scores were evaluated; (2) tissue (general/immune) mast cells and CCR3(+) eosinophils, as well as vascular endothelial growth factor, fibroblast growth factor, and epidermal growth factor immunoreactive changes were evaluated; (3) CD4(+) and CD8(+) cells in the spleen were immunohistochemically examined; and, (4) the serum immunoglobulin (Ig)E level and lymphokines [interleukin (IL)-2, IL-4] were measured. In the PPI and the PPIII groups, the clinical skin score, total number of mast cells, CCR3(+) eosinophils immunoreaction, and total serum IgE, IL-2, and IL-4 levels were lower than the control group. The PPI and the PPIII groups also showed strong immunohistochemical reactions for vascular endothelial growth factor and fibroblast growth factor. The PPI group particularly showed a very strong immunohistochemical reaction for epidermal growth factor. All groups showed strong immune activity for CD8(+). The PPIII group showed strong immunity for both CD4(+) and CD8(+). From the above results,
Rehmanniae radix pharmacopuncture (MeOH extraction) and anti-inflammatory pharmacopuncture exerted
anti-allergic and anti-inflammatory effects, suggesting that they are promising agents for improving
J Acupunct Meridian Stud. 2013 Apr;6(2):98-109. doi: 10.1016/j.jams.2012.10.007. Epub 2012 Nov 30.
Acupuncture in the Treatment of Upper-Limb Lymphedema
Cassileth BR, et al. Integrative Medicine Service, Memorial
Sloan-Kettering Cancer Center, New York, New York.
BACKGROUND: Current treatments for lymphedema after breast cancer treatment are expensive and require ongoing intervention. Clinical experience and our preliminary published results suggest that acupuncture is safe and potentially useful. This study evaluates the safety and potential efficacy of acupuncture on upper-limb circumference in women with lymphedema. METHODS: Women with a clinical diagnosis of breast cancer-related lymphedema (BCRL) for 0.5-5 years and with affected arm circumference ≥2 cm larger than unaffected arm received acupuncture treatment twice weekly for 4 weeks. Affected and unaffected arm circumferences were measured before and after each acupuncture treatment. Response, defined as ≥30% reduction in circumference difference between affected/unaffected arms, was assessed. Monthly follow-up calls for 6 months thereafter were made to document any complications and self-reported lymphedema status. RESULTS: Among 37 enrolled patients, 33 were evaluated; 4 discontinued due to time constraints. Mean reduction in arm circumference difference was 0.90 cm (95% CI, 0.72-1.07; P < .0005). Eleven patients (33%) exhibited a reduction of ≥30% after acupuncture treatment. Seventy-six percent of patients received all treatments; 21% missed 1 treatment, and another patient missed 2 treatments. During the treatment period, 14 of the 33 patients reported minor complaints, including mild local bruising or pain/tingling. There were no serious adverse events and no infections or severe exacerbations after 255 treatment sessions and 6 months of follow-up
interviews. CONCLUSIONS: Acupuncture for BCRL appears safe and may reduce arm circumference. Although
these results await confirmation in a randomized trial, acupuncture can be considered for women with no
other options for sustained arm circumference reduction.
Cancer.Apr 10. doi: 10.1002/cncr.28093.